Related Experiment Video
Updated: Dec 23, 2025
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
[Retroperitoneal lymph node assessment in pediatric paratesticular rhabdomyosarcoma]
Florent Guérin1, Hélène Martelli1
1Hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, chirurgie pédiatrique, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France.
Insights
Paratesticular rhabdomyosarcoma impacts children, with older patients facing poorer survival. Early detection and assessment of retroperitoneal lymph nodes are crucial for improving outcomes in pediatric rhabdomyosarcoma.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Medical Imaging
Background:
- Paratesticular rhabdomyosarcoma represents a significant subset of pediatric rhabdomyosarcomas.
- Event-free survival rates are notably lower for children over 10 years old compared to younger children.
- Relapses frequently occur in retroperitoneal lymph nodes, often leading to fatal outcomes.
Purpose of the Study:
- To evaluate the effectiveness of different retroperitoneal lymph node assessment strategies in pediatric paratesticular rhabdomyosarcoma.
- To identify methods for improving event-free survival, particularly in older children with larger tumors.
- To inform future European protocols for managing retroperitoneal lymph node involvement.
Main Methods:
- Comparison of European (imaging-based) and American (lymph node dissection) protocols for retroperitoneal lymph node assessment.
- Analysis of event-free survival data based on patient age and tumor size.
- Proposed changes to the European protocol including surgical biopsy for enlarged nodes and assessment for older patients with non-enlarged nodes.
Main Results:
- Retroperitoneal lymph node dissection has demonstrated improved event-free survival in patients over 10 years with tumors larger than 5cm.
- Current imaging-based assessment in European protocols may not be sufficient for all patient subgroups.
- The proposed protocol changes aim to enhance the accuracy and effectiveness of lymph node staging.
Conclusions:
- Optimizing retroperitoneal lymph node assessment is critical for improving outcomes in pediatric paratesticular rhabdomyosarcoma.
- Future protocols will incorporate surgical biopsies and refined assessment strategies for specific age and tumor size groups.
- Investigating novel techniques like sentinel node biopsies and PET-scans may further advance lymph node staging.
Abstract:
Paratesticular Rhabdomyosarcoma accounts for 7 to 11% of pediatric rhabdomyosarcomas. Children older than 10 years have a worse event-free survival (69 to 80% vs. 87 to 92%) than children younger than 10 years. In this location, the relapses are essentially in the retroperitoneal lymph nodes and are often fatal. In European protocols, the assessment of the retroperitoneal lymph nodes at diagnosis is made by imaging whereas it is performed by retroperitoneal lymph node dissection in the American protocols. This method has been proved to improve event-free survival in the group of patient older than 10 years with a tumour bigger than 5cm. In the next European protocol, when nodes will be enlarged a surgical biopsy will be performed, this will be irrespective of age or size, and when no nodes will be enlarged in patients older than 10 years, retroperitoneal lymph node assessment will be performed. Other techniques of lymph nodes assessment will be tested like sentinel node biopsies or PET-scan.
